Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men

被引：13

作者：

Chaudry, NI

Eron, JJ

Naderer, OJ

Pereira, AS

Wire, MB

Fiscus, SA

Kashuba, ADM

机构：

[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA

[2] Univ N Carolina, Sch Med, Chapel Hill, NC USA

[3] GlaxoSmithKline, Res Triangle Pk, NC USA

来源：

CLINICAL INFECTIOUS DISEASES | 2002年 / 35卷 / 06期

关键词：

D O I：

10.1086/342389

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We compared seminal plasma pharmacokinetic data for the investigational amprenavir prodrug GW433908 with those for amprenavir and an amprenavir-ritonavir combination regimen. All 3 regimens resulted in detectable blood plasma and seminal plasma concentrations of amprenavir. The majority of these concentrations were greater than the plasma protein-corrected 50% inhibitory concentration for wild-type human immunodeficiency virus type 1.

引用

收藏

页码：760 / 762

页数：3

相关论文

共 15 条

[1] The effect of water-soluble vitamin E On cyclosporine pharmacokinetics in healthy volunteers [J].

Chang, T ;

Benet, LZ ;

Hebert, MF .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (03) :297-303

[2] The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850) [J].

Eron, JJ ;

Smeaton, LM ;

Fiscus, SA ;

Gulick, RM ;

Currier, JS ;

Lennox, JL ;

D'Aquila, RT ;

Rogers, MD ;

Tung, R ;

Murphy, RL .

JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (05) :1622-1628

[3] Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission [J].

Eron, JJ ;

Vernazza, PL ;

Johnston, DM ;

Seillier-Moiseiwitsch, S ;

Alcorn, TM ;

Fiscus, SA ;

Cohen, MS .

AIDS, 1998, 12 (15) :F181-F189

[4]

*GLAX SMITHKL, 2001, AG PACK INS

[5] Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1 [J].

Kashuba, ADM ;

Dyer, JR ;

Kramer, LM ;

Raasch, RH ;

Eron, JJ ;

Cohen, MS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1817-1826

[6] Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus [J].

Molla, A ;

Vasavanonda, S ;

Kumar, G ;

Sham, HL ;

Johnson, M ;

Grabowski, B ;

Denissen, JF ;

Kohlbrenner, W ;

Plattner, JJ ;

Leonard, JM ;

Norbeck, DW ;

Kempf, DJ .

VIROLOGY, 1998, 250 (02) :255-262

[7]

PEREIRA A, 2001, 8 C RETR OPP INF CHI, P271

[8] Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor [J].

Polli, JW ;

Jarrett, JL ;

Studenberg, SD ;

Humphreys, JE ;

Dennis, SW ;

Brouwer, KR ;

Woolley, JL .

PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1206-1212

[9] Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers [J].

Sadler, BM ;

Piliero, PJ ;

Preston, SL ;

Lloyd, PP ;

Lou, Y ;

Stein, DS .

AIDS, 2001, 15 (08) :1009-1018

[10] Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing [J].

Sadler, BM ;

Gillotin, C ;

Lou, Y ;

Stein, DS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :30-37